Relationship between acute improvement in left ventricular function to 6-month outcomes after cardiac

Luis A Pires1, Stefano Ghio, Eugene S Chung

  • 1Heart Rhythm Center, St John Hospital and Medical, Moross, Detroit, MI 48236, USA. luis.pires@stjohn.org

Insights

An acute increase in left ventricular ejection fraction after cardiac resynchronization therapy does not predict long-term heart failure outcomes. However, this acute response in patients with smaller left ventricular volumes may offer insights into CRT mechanisms.

Area of Science:

  • Cardiology
  • Heart Failure Management
  • Medical Devices

Background:

  • Cardiac resynchronization therapy (CRT) is a treatment for heart failure (HF).
  • The long-term impact of acute improvements in left ventricular (LV) function following CRT is not well understood.
  • Predicting CRT response is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To evaluate the significance of acute improvements in LV function after CRT.
  • To determine if an acute increase in LV ejection fraction (EF) predicts 6-month clinical outcomes and reverse remodeling.
  • To explore potential mechanisms underlying CRT benefits.

Main Methods:

  • Retrospective analysis of CRT-treated patients from the PROSPECT trial.
  • Comparison of 6-month clinical composite score (CCS) and LV end-systolic volume (ESV) reduction rates.
  • Stratification based on acute (≥15%) increase in LV ejection fraction (EF) post-CRT.

Main Results:

  • 19.7% of patients showed an acute increase in LVEF; these patients had lower baseline EF and smaller LV volumes.
  • At 6 months, CCS improvement (70.5% vs. 69.5%) and LVESV reduction (57.1% vs. 54.9%) response rates were similar between groups.
  • An acute LVEF increase did not predict 6-month CRT effects on patient outcomes or LV reverse remodeling.

Conclusions:

  • An acute significant increase in LVEF following CRT does not reliably predict long-term clinical benefit or reverse remodeling.
  • The findings suggest that acute functional response in patients with smaller LV volumes may offer insights into CRT's mechanisms of action.
  • Further research is needed to fully elucidate the factors influencing long-term CRT efficacy.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...